Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Treatment of nasal symptoms of seasonal and perennial allergic rhinitis; prophylaxis of nasal symptoms of seasonal allergic rhinitis; relief of nasal congestion associated with seasonal allergic rhinitis; treatment of nasal polyps.
Maintenance treatment of asthma as prophylactic therapy in patients 4 y and older.
Adults and Children 12 y and older:Intranasal 2 sprays in each nostril once daily.
Children 2 to 11 y of age:Intranasal 1 spray in each nostril once daily.
Adults and Children 12 y and older:Oral inhalation Initially, 220 mcg once daily in the evening in patients who previously received bronchodilators alone or inhaled corticosteroids (max, 440 mcg/day); 440 mcg twice daily in patients who previously received oral corticosteroids (max, 880 mcg/day). In patients who do not adequately respond to the initial dose after 2 wk of therapy, higher doses may provide additional control. Titrate to lowest effective dose once asthma stability is achieved.
Children 4 to 11 y of age:Oral inhalation 110 mcg once daily in the evening (max, 110 mcg/day).
Cream and ointment
Adults and Children 2 y and olderTopical Apply a thin film to the affected areas once daily. Discontinue when control is achieved. If no improvement is seen within 2 wk, reassess diagnosis.
Adults and Children 12 y and olderTopical Apply a few drops to the affected area once daily and massage lightly until it disappears.
Adults:Intranasal 2 sprays in each nostril twice daily. A dose of 2 sprays in each nostril once daily is also effective in some patients.
Medium-potency topical corticosteroid that depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complement system; modifies the body’s immune response.
Primary treatment of status asthmaticus or other acute episodes of asthma in which intensive measures are required, hypersensitivity to milk proteins ; hypersensitivity to any component of the product.
Sinusitis (22%); upper respiratory tract infection (15%); sinus congestion (9%); dysphonia, epistaxis, nasal irritation, respiratory disorder (1% to less than 3%); asthma aggravation, which may include cough, dyspnea, wheezing, and bronchospasm (postmarketing). OTHER: Systemic absorption may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing syndrome, hyperglycemia, and glycosuria.